Navigation Links
Falcon Genomics Awarded Patent for Innovative Cancer Test
Date:5/28/2009

Patent Covers High-throughput, Anchorage-independent Assay for Screening Compounds for Inhibition of Cancer Cell Growth.

PITTSBURGH, May 28 /PRNewswire/ -- Falcon Genomics, Inc. announced today that it has received U.S. Patent # 7,537,913 with claims covering the Company's Cancer BioChip System (CBCS) for the identification and validation of potential cancer targets in a high-throughput in vitro setting with great clinical translational potential.

The patent claims are supported by experimental validation with human breast cancer cells using Falcon Genomics' first-generation Cancer BioChip System (CBC-1). These results, recently presented at the 6th Annual Conference on Cancer Drugs Research and Development in Philadelphia, PA (February 19, 2009) represent the first reported use of high-throughput one-step delivery of silencing RNA (siRNA) into cells growing in an anchorage-independent manner with real-time evaluation of cell growth.

"Cancer is analogous to a physiological train-wreck. It only takes a small number of defective signals to trigger the multitudes of abnormal molecular profiles observed within cancer cells. Triggering molecules are the ones that must be targeted for therapy," said Dr. Rula Abbud-Antaki, President and Chief Scientific Officer of Falcon Genomics. "Our proprietary technology will provide personalized identification of cancer- initiating events, and formulation of efficient and accurate therapies."

According to Dr. Peter D. Mlynek, a patent attorney with the law firm of Eckert Seamans, the Cancer BioChip System is a unique and highly useful technology. "The U.S. Patent Office has found the claimed CBCS to be novel and non-obvious."

About Falcon Genomics, Inc.

Falcon Genomics, Inc. is a private Pittsburgh-based biotech company founded in August 2004. The goal of the company is to provide cutting edge technologies, including functional genomics, for the accurate diagnosis of cancer patients and the personalized formulation of therapeutic strategies. Falcon Genomics currently provides CBCS services for research and pharmaceutical institutions working at the forefront of cancer diagnostics and therapeutics.

For more information, please visit: www.falcongenomics.com


'/>"/>
SOURCE Falcon Genomics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
2. FalconStor Software Inc. Founders Make Multi-Million Dollar Donation to North Shore-LIJ Health System for Asian Community Health Center in Flushing
3. Atlanta Falcons Linebacker Keith Brooking Prepares to Run for Something Better at ING Georgia Marathon
4. MessageSolution and FalconStor Deliver Turnkey Solution for Enterprise Archiving, DR, and High-Availability
5. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
6. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
7. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test:
8. NeoGenomics, Inc. Schedules its Q3 07 Earnings Conference Call For Wednesday, November 14, 2007 at 11:00 AM
9. NeoGenomics Announces Results for the 3rd Quarter 2007
10. Rosetta Genomics Strengthens Senior Management in Preparation for its First Commercial Launch of microRNA-Based Diagnostic Products in 2008
11. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 02, 2016 , ... "Pro3rd Accents Volume ... editors to create versatile lower third titles with just a few clicks of the ... Volume 2 includes 30 lower third animations. Choose from various styles with accented animations, ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... to needy individuals and families from eight different sites throughout Miami-Dade and Broward ... Over 1,000 volunteers worked very hard on Thanksgiving morning by putting together individual ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... Laboratory Scientist & Author of Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein ... Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health radio ...
(Date:11/30/2016)... Massachusetts (PRWEB) , ... November 30, 2016 , ... ... proud to announce that we have been designated as a Cigna Infertility Center ... or exceed rigorous performance standards. , “It’s an honor to be designated ...
(Date:11/30/2016)... ... 30, 2016 , ... "I hate when the mixture of saliva and toothpaste ... an inventor from Bridgewater, N.J. "I thought that there had to be a way ... developed the patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the brush ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, hat sein ... eingeführt. Continue Reading ... ... , ... ) bioLytical wurde durch die Clinton Health Access ...
(Date:12/2/2016)... , Dec. 2, 2016   CytoSorbents Corporation ... commercializing its European Union approved CytoSorb ® cytokine ... surgery patients worldwide, announced that Dr. Phillip Chan ... 9th Annual LD Micro Main Event investor conference ... at the Luxe Sunset Boulevard Hotel in ...
(Date:12/2/2016)... LYME, Conn. , Dec. 1, 2016  Today, ... has announced the honor of being selected as winners ... include: Simpson Healthcare Executives Website at the PLATINUM level, ... Conversations Training Module at the GOLD Level, and our ... At Simpson Healthcare Executives, we are excited ...
Breaking Medicine Technology: